Tempest Therapeutics, Inc. (TPST)
- Previous Close
3.4400 - Open
3.3700 - Bid 3.4500 x 400
- Ask 3.5000 x 100
- Day's Range
3.3100 - 3.4800 - 52 Week Range
0.1700 - 9.7700 - Volume
287,166 - Avg. Volume
989,279 - Market Cap (intraday)
77.316M - Beta (5Y Monthly) -2.83
- PE Ratio (TTM)
-- - EPS (TTM)
-1.9100 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.60
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
www.tempesttx.comRecent News: TPST
Performance Overview: TPST
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TPST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TPST
Valuation Measures
Market Cap
77.32M
Enterprise Value
58.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.89
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.12
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.31%
Return on Equity (ttm)
-131.42%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-29.49M
Diluted EPS (ttm)
-1.9100
Balance Sheet and Cash Flow
Total Cash (mrq)
39.23M
Total Debt/Equity (mrq)
77.18%
Levered Free Cash Flow (ttm)
-17.47M